Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?

Abstract

British Journal of DermatologyVolume 170, Issue 5 p. 1198-1199 Correspondence Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist? M. Tauber, M. Tauber Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, France Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, FranceSearch for more papers by this authorM. Viguier, M. Viguier Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, FranceSearch for more papers by this authorC. Le Gall, C. Le Gall Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, FranceSearch for more papers by this authorA. Smahi, A. Smahi Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, FranceSearch for more papers by this authorH. Bachelez, Corresponding Author H. Bachelez Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, France Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, France Correspondence: Hervé Bachelez. E-mail:herve.bachelez@sls.aphp.frSearch for more papers by this author M. Tauber, M. Tauber Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, France Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, FranceSearch for more papers by this authorM. Viguier, M. Viguier Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, FranceSearch for more papers by this authorC. Le Gall, C. Le Gall Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, FranceSearch for more papers by this authorA. Smahi, A. Smahi Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, FranceSearch for more papers by this authorH. Bachelez, Corresponding Author H. Bachelez Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015 Paris, France Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, France Correspondence: Hervé Bachelez. E-mail:herve.bachelez@sls.aphp.frSearch for more papers by this author First published: 24 December 2013 https://doi.org/10.1111/bjd.12805Citations: 23 Funding sources: none. Conflicts of interest: H.B. has been involved with Abbvie, Amgen, Boehringer, Celgene, Janssen, Eli-Lilly, Novartis and Pfizer; M.V. with Abbvie, Novartis and Pfizer; and A.S. with Pfizer. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article.Citing Literature Volume170, Issue5May 2014Pages 1198-1199 RelatedInformation